Stockscreener 앱 받기
15.55
3.67%
0.55
시간 외 거래:
15.40
-0.15
-0.96%
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
Mineralys Therapeutics to Announce Q4 and Full-Year 2024 Financial Results - MyChesCo
This Intuitive Machines Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
TD Cowen Initiates Palvella Therapeutics at Buy With $44 Price Target -February 05, 2025 at 07:50 am EST - Marketscreener.com
TD Cowen Initiates Coverage on Palvella Therapeutics (NASDAQ:PVLA) - MarketBeat
Cowen initiates Palvella Therapeutics with buy, $44 target By Investing.com - Investing.com UK
Palvella Therapeutics Kicks Off Phase 2 Trial for Promising Cutaneous VM Treatment - MSN
Research Analysts Issue Forecasts for PVLA FY2025 Earnings - Defense World
Palvella Therapeutics Reports Promising Results for QTORIN Rapamycin in Treating Rare Genetic Disease - MSN
Palvella Therapeutics’ (PVLA) Buy Rating Reiterated at HC Wainwright - Defense World
Palvella reports positive phase 2 study on QTORIN rapamycin for rare skin disease - Investing.com India
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies - The Manila Times
Palvella Therapeutics Announces Publication of Results from - GlobeNewswire
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations - The Manila Times
Palvella Therapeutics Announces First Patients Dosed in - GlobeNewswire
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN - The Bakersfield Californian
Brokers Issue Forecasts for PVLA FY2029 Earnings - Defense World
Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments - MSN
Palvella Therapeutics (NASDAQ:PVLA) Given Buy Rating at HC Wainwright - Defense World
Palvella Therapeutics registers 5.6M shares by selling holders - MSN
Analysts Issue Forecasts for PVLA FY2024 Earnings - Defense World
What is HC Wainwright’s Estimate for PVLA Q4 Earnings? - Defense World
Palvella Therapeutics initiated with a Buy at H.C. Wainwright - Yahoo Finance
Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Analysts at HC Wainwright - Defense World
Palvella Therapeutics stock gains attention with Phase 3 trial data expected in early 2026 - Investing.com Canada
Pieris Pharmaceuticals: Q1 Earnings Snapshot - Marketscreener.com
Wayne’s Palvella Therapeutics Completes Reverse Merger with Pieris Pharmaceutical - MSN
Palvella therapeutics director George Jenkins acquires $51,720 in shares By Investing.com - Investing.com Canada
Palvella therapeutics director George Jenkins acquires $51,720 in shares - Investing.com
Pieris Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2021 - Marketscreener.com
Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific - Marketscreener.com
Larimar Therapeutics Reports Promising Results for Friedreich’s Ataxia Treatment - MyChesCo
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 - Marketscreener.com
Palvella Therapeutics closes on Pieris merger; completes nearly $80M private placement - Pennsylvania Business Report
After losing AstraZeneca collab, Boston biotech opts for reverse merger - The Business Journals
Main Line biotech firm completes reverse merger, raises $78.9 million - The Business Journals
Palvella Therapeutics Closes Merger with Pieris Pharmaceuticals - citybiz
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346) - Marketscreener.com
Pieris Pharmaceuticals: Q3 Earnings Snapshot - Marketscreener.com
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc.PIRS - Marketscreener.com
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million - The Manila Times
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent - The Bakersfield Californian
Palvella Therapeutics Announces Closing of Merger with - GlobeNewswire
1.03%
자본화:
|
볼륨(24시간):